In this short review of haemolytic anaemias, general principles of diagnosis and a classification of the various types will be considered first. The well-established advances made during recent years in the understanding of the cause and mechanism of certain haemolytic anaemias will then be surveyed.
The Normal Life Span and Destruction of Red Cells
It is now known with certainty that normal red cells in healthy persons survive about ICO to I20 days. Studies of the rates of disappearance of transfused normal cells (Mollison and Young, 1942) , of cells containing sulphaemoglobin (Jope, 1946) , and of cells containing the nitrogen isotope N15 (Shemin and Rittenburg, 1946) have all given such a value for the life span of a red cell. Little is known of the physiological destruction of red cells at the end of their life, but it is possible that the cells undergo fragmentation and that the fragments are engulfed by the phagocytic cells of the reticulo-endothelial system. The haemoglobin liberated by red-cell destruction is broken down into iron, which is re-utilized, and bilirubin. Most of the bilirubin (but not all of it) is eventually excreted in the faeces as urobilinogen, at least II per cent. of the total faecal urobilinogen is derived from sources other than the breakdown of haemoglobin (London et al., I950). Nevertheless, the amount of urobilinogen in the faeces is a rough guide to the rate of red cell destruction, if considered in relation to the total haemoglobin of the body. Normally, about II to 21 mg. of urobilinogen are excreted per day per Ioo gm. of haemoglobin (Miller et al., 1942) .
The Diagnosis of Haemolytic Aiiaemia
The haemolytic anaemias are characterized by an increased rate of red cell destruction, the life of the cells being reduced, even to a very few days.
Hence large amounts of bilirubin arK Jormed, the serum bilirubin is raised and jaundice is apparent, and the faecal urobilinogen excretion is increased.
The urine does not contain bile pigments but larger amounts than the normal traces of urobilinogen are usually present. Occasionally a normal serum bilirubin level is found when a patient's liver can excrete the excess bilirubin without any accumulating in the blood stream.
In response to the increased haemolysis, red cell production is accelerated. (Young et al., 195sa ) and undergo spontaneous lysis or ' auto-haemolysis' (Dacie, I941) more rapidly than normal. These rapid changes, which may be due to degeneration of the cell membranes, probably occur while blood is stagnating in vivo in the spleen. The spleen is certainly the major site of haemolysis, as its removal invariably results in a complete or almost complete cure of the anaemia. The red cell defect, of course, is unaltered and the spherocytosis persists, although usually to a lesser degree than before splenectomy (Dacie, I943) as the harmful effects of stagnation in the spleen no longer exist.
A feature of hereditary spherocytosis is the occurrence of sudden relapses, often following infections. The sudden increase in anaemia is, at least in many instances, due to decreased red cell production and not to increased haemolysis (Owren, 1948) . Leucocyte and platelet production are also diminished; it is an' aplastic ' rather than a haemolytic crisis.
Patients with hereditary spherocytosis should be advised to undergo splenectomy unless the disease is very mild. The dangers of sudden crises, pigment stores in the gall-bladder, and chronic anaemia are easily outweighed by the prospect of certain relief (if diagnosis is correct), and the present-day risks of splenectomy are small. Thalassaemia is again an inherited and congenital disease, the thalassaemia gene in the homozygous state causing thalassaemia major or Cooley's anaemia, and in the heterozygous state causing thalassaemia minor. This gene apparently inhibits the synthesis of normal adult haemoglobin, the red cells being hypochromic and microcytic, and target cells are common. The osmotic fragility is reduced. The minor disease varies in severity from a condition with moderate anaemia to one with no anaemia in which the life span of the cells is normal (Kaplan and Zuelzer, 1950 
destroyed more rapidly than normal. The mechanism of destruction is uncertain; one probable mechanism is the phagocytosis of the sensitized cells in the spleen and other organs. The cells of about 75 per cent. of the patients show spherocytosis, a secondary change due to the action of antibodies; this change al4o appears to lead to haemolysis in the spleen and elsewhere.
Splenectomy produces a remission of the haemolytic ainaemia in only about 50 per cent. of patients (Dameshek, I950) . For this and the following three reasons, it should be considered only as a last resort in the treatment of a patient. Firstly, spontaneous remissions occasionally occur and can be apparently permanent. Secondly, certain neoplastic conditions (e.g. chronic lymphatic leukaemia and reticulo-sarcoma) are occasionally associated with a secondary haemolytic anaemia due to auto-antibodies. The neoplasm may be obscure and may not become apparent until after the haemolytic anaemia has been present for some while. Thirdly, and most important, the administration of ACTH or cortisone in sufficient dosage results in a moderate or complete relief of anaemia in the majority of patients, together with a decrease in the degree of sensitization of the red cells (Dameshek, I952) . These remissions are probably due to inhibition of the production of antibodies and last for varying periods of time. Hence treatment with ACTH or cortisone should have a thorough trial before splenectomy is considered.
The sera of patients with acquired haemolytic anaemia may contain moderately strong cold autoantibodies which are inactive at body temperatures. Occasionally, however, patients are seen with no warm auto-antibodies in the blood; instead, their sera contain potent cold antibodies optimally active in the cold but with a high thermal range. The cold incomplete antibodies are active even up to 370 C., thereby sensitizing the patients' red cells in vivo and causing a chronic haemolytic anaemia. The (Dacie, 1950) . This type of haemoglobinuria is not associated with syphilis.
Paroxysmal Cold Haemoglobinuria
Paroxysmal cold haemoglobinuria is a rare disorder, characterized by episodes of intravascular haemolysis which take place when the patient has become chilled and by the consequent haemoglobinuria. A chronic haemolytic anaemia is usually not present, and in most, but not all, cases the patients have a syphilitic infection. The sera of all patients contain the Donath-Landsteiner lysin. This lysin (demonstrable in vitro with unacidified sera) is adsorbed with complement on to the patients' red cells in the cold; the cells are lysed by further amounts of complement when they circulate again in warm parts of the body.
Haemolytic Anaemia Following Virus Pneumonia
The high-titre auto-antibodies commonly found in the sera of patients with virus pneumonia may occasionally cause an aute haemolytic episode in the later stages of the illness if they have a sufficiently high thermal range (Dacie and de Gruchy, I95I).
Haemolytic Disease of the Newborn
The causal antibodies of haemolytic disease of the newborn are formed in the mother and are isoantibodies, active against particular blood group factors. Further consideration of this disease will have to be omitted from this review.
Anaemias of Uncertain Pathogenesis
Haemolytic cases of chronic myeloid leukaemia seem to be more satisfactory and longer lasting than those usually obtained after treatment with other drugs. In a few cases remissions can be obtained after the disease has ceased to respond satisfactorily to irradiation and reduction of troublesome and radio-resistant splenic enlargement will follow Myleran treatment in most instances. Myleran is useless in acute leukaemia and in the acute myeloid crisis of chronic leukaemia.
The dose of Myleran should not exceed 4 mg. daily. During the second or third week the leucocyte count begins to fall, but normal levels may not be reached before three or four months. The treatment is continued with frequent bloodcount control, provided that the improvement is maintained and that there is no reduction of platelets to less than ioo,ooo per cu. mm. Higher doses of Myleran are likely to cause thrombocytopenia or general marrow aplasia.
As in TEM, experience is as yet too restricted to be certain that the prolonged administration of Myleran has no deleterious effect on normal marrow function and the use of these drugs might therefore remain confined for the present to cases in which irradiation or nitrogen mustards are contra-indicated or are no longer effective.
Radiotherapy and the present forms of chemotherapy in leukaemia act by a purely repressive or destructive effect on malignant cells. The selectivity of this effect is only one of degree and the hope for the future must lie with the development of methods which will either damage malignant cells exclusively, or better still, restore the normal control-mechanism which regulates mitosis and differentiation of cells in accordance with the needs of the body.
